UMB Bank NA filed suit against Bristol Myers in 2021, alleging the company intentionally slow-rolled the approval process for ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Shattuck Labs STTK announced its decision to discontinue the development of its pipeline candidate SL-172154, which was being ...

Celgene paid $7.2 billion to acquire Receptos and its multiple sclerosis hopeful ozanimod in 2015 – but it has hit a major setback after the FDA refused to accept its dossier. The New Jersey ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...

Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of ...

Evotec and Celgene partnered up in October 2017 to work on degenerative diseases, including Alzheimer’s. They signed a five-year agreement whereby Evotec received an upfront payment of €43m ...